Scinai Immunotherapeutics (SCNI) Net Cash Flow (2018 - 2026)
Scinai Immunotherapeutics (SCNI) posted Net Cash Flow of $1.3 million for Q1 2026, up 2271.67% sequentially from -$60000.0 in Q2 2025, and up 237.74% YoY from $385802.2 in Q1 2025.
Scinai Immunotherapeutics (SCNI) Net Cash Flow (2018 - 2026) Analysis & Trends
Scinai Immunotherapeutics has reported Net Cash Flow for 9 years, with the latest figure at $1.3 million in Q1 2026.
- Quarterly Net Cash Flow rose 237.74% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $297000.0 (up 107.79% YoY) and the FY2025 annual result came in at -$285000.0, up 90.19% from the prior year.
- Net Cash Flow climbed to $1.3 million in Q1 2026 per SCNI's latest filing, from -$60000.0 in the prior quarter.
- Over five years, Net Cash Flow peaked at $1.3 million in Q1 2026 and troughed at -$4.2 million in Q2 2022.
- A 5-year average of -$1.4 million and a median of -$1.6 million in 2022 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2025 and 2026: Net Cash Flow slumped 2265.0% in 2025, then soared 237.74% in 2026.
- Over 5 years, Net Cash Flow stood at -$863000.0 in 2022, then slumped by 162.46% to -$2.3 million in 2023, then surged by 139.74% to $900000.0 in 2024, then tumbled by 106.67% to -$60000.0 in 2025, then surged by 2271.67% to $1.3 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered $1.3 million, -$60000.0, and -$946000.0 for Q1 2026, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Scinai Immunotherapeutics | 11.72 Mn | -3.10 Bn | -1.12 Mn | 1.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.30 Mn |
| Mar 31, 2026 | 1.30 Mn |
| Jun 30, 2025 | -60,000.00 |
| Jun 30, 2025 | -60,000.00 |
| Mar 31, 2025 | -946,000.00 |
| Mar 31, 2025 | -946,000.00 |
| Dec 31, 2024 | 900,000.00 |
| Dec 31, 2024 | 900,000.00 |
| Sep 30, 2024 | -2.01 Mn |
| Sep 30, 2024 | -2.01 Mn |
| Jun 30, 2024 | -1.76 Mn |
| Jun 30, 2024 | -1.76 Mn |
| Mar 31, 2024 | -40,000.00 |
| Mar 31, 2024 | -40,000.00 |
| Dec 31, 2023 | -2.27 Mn |
| Dec 31, 2023 | -2.27 Mn |
| Sep 30, 2023 | -1.44 Mn |
| Sep 30, 2023 | -1.44 Mn |
| Jun 30, 2023 | -3.25 Mn |
| Jun 30, 2023 | -3.25 Mn |